The Neuronal Apoptosis Inhibitory Protein Is a Direct Inhibitor of Caspases 3 and 7

Total Page:16

File Type:pdf, Size:1020Kb

The Neuronal Apoptosis Inhibitory Protein Is a Direct Inhibitor of Caspases 3 and 7 The Journal of Neuroscience, March 15, 2002, 22(6):2035–2043 The Neuronal Apoptosis Inhibitory Protein Is a Direct Inhibitor of Caspases 3 and 7 Johannes K. X. Maier,1,2 Zahia Lahoua,1 Nathalie H. Gendron,1 Raouf Fetni,1 Anne Johnston,1 Jamshid Davoodi,1 Dita Rasper,4 Sophie Roy,4 Ruth S. Slack,3 Donald W. Nicholson,4 and Alex E. MacKenzie1,2,5 1Solange Gauthier Karsh Laboratory, Children’s Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada K1H 8L1, 2Department of Biochemistry, Microbiology, and Immunology, and 3Neuroscience Research Institute, University of Ottawa, Ottawa, Ontario, Canada K1H 8M5, 4Merck Frosst Canada Inc., Kirkland, Quebec, Canada H9H 3L1, and 5Aegera Therapeutics Inc., Ottawa, Ontario, Canada K1H 8M5 The neuronal apoptosis inhibitory protein (NAIP) was identified cells transiently transfected with a NAIP N-terminal construct and as a candidate gene for the inherited neurodegenerative disor- treated to undergo a caspase-3-dependent cell death. To examine der spinal muscular atrophy. NAIP is the founding member of a whether NAIP inhibits caspases directly, recombinant N-terminal human protein family that is characterized by highly conserved NAIP protein containing BIR domains was overexpressed, puri- N-terminal motifs called baculovirus inhibitor of apoptosis repeats fied, and tested for caspase inhibition potential. Our results dem- (BIR). Five members of the human family of inhibitor of apoptosis onstrate that inhibition of caspases is selective and restricted to ϳ proteins including NAIP have been shown to be antiapoptotic in the effector group of caspases, with Ki values as low as 14 nM for various systems. To date, a mechanism for the antiapoptotic effect caspase-3 and ϳ45 nM for caspase-7. Additional investigations of NAIP has not been elucidated. To investigate NAIP function, we with NAIP fragments containing either one or two NAIP BIRs found cytoprotection of NAIP-expressing primary cortical neurons revealed that the second BIR and to a lesser extent the third BIR treated to undergo caspase-3-dependent apoptosis. The addi- alone are sufficient to mediate full caspase inhibition. tional treatment of these neurons with the pancaspase inhibitor boc-aspartyl(OMe)-fluoromethylketone did not result in increased Key words: BIR domains; NAIP; caspase inhibition; neuronal survival. Similar cytoprotective effects were obtained using HeLa apoptosis; inhibitor of apoptosis protein family; cytoprotection With the discovery of biochemical and histological hallmarks of baculoviral inhibitor of apoptosis proteins (IAPs) Cp-IAP and apoptosis, it has become increasingly evident that the intrinsic Op-IAP. NAIP is the founding member of the human IAP cellular suicide program is not only required for normal CNS protein family (Roy et al., 1995), which typically express one to development (Oppenheim, 1991) but also, if executed inappro- three motifs in the N-terminal region termed baculovirus inhibi- priately, contributes to the pathology of neurodegenerative dis- tor of apoptosis repeat (BIR) domains that are defined by a orders such as Alzheimer’s disease (Cotman, 1998), Parkinson’s CX2CX16HX6–8C consensus sequence (Uren et al., 1998). disease (Hartmann et al., 2000), or the childhood spinal muscular Recent studies examining neuronal cell death indicate a key atrophy (SMA; Morrison, 1996). The defining characteristic of role for caspase-3 in the apoptotic process. For example, it has SMA is a progressive loss of motor neurons leading to wasting of been shown that caspase-3 knock-out mice show severe alter- the voluntary muscles. SMA patients are clinically heterogeneous ations of brain structures in regions where neuronal apoptosis is and are classified into three types (types I–III) on the basis of age predominantly believed to occur. The changes include an overall of onset, severity, and clinical progression (Morrison, 1996). The brain mass increase, disorganized cell deployment, and dupli- ϳ combined frequency for all three types of SMA is 1:10,000, cated brain structures (Kuida et al., 1996). In addition, upregula- making it one of the most common inherited neurodegenerative tion and activation of caspase-3 or a caspase-3-like protease has diseases (Emery, 1991). Analysis of the complex SMA locus that been shown to be a key mediator of neuronal death in neurons maps to chromosome 5q13 has led to the discovery of two can- after excitotoxic and hypoxic injuries, as well as in the hippocam- didate genes for SMA, the SMA-causing gene survival motor pal CA1 sector after transient global ischemia (Yakovlev et al., neuron (SMN) and the potential modifier neuronal apoptosis 1997; Chen et al., 1998; Namura et al., 1998; Ni et al., 1998). inhibitory protein (NAIP; Lefebvre et al., 1995; Roy et al., 1995). An antiapoptotic effect of NAIP and other members of the The NAIP gene coding region spans 4212 nucleotides encoding a human IAP family has been shown in cell culture systems (Liston 1403-amino acid 156 kDa protein with strong homology to the et al., 1996; Deveraux and Reed, 1999). Apoptotic hippocampal neurons can be rescued by stereotactic microinjection of NAIP- Received May 18, 2001; revised Oct. 30, 2001; accepted Nov. 6, 2001. expressing adenovirus in the CA1 region, suggesting that the This work was supported by grants from the Canadian Institutes of Health Research, the Muscular Dystrophy Association of Canada, and Aegera Therapeutics antiapoptotic activity of NAIP shown in vitro extends to the in Inc. A.E.M. is a Burroughs-Wellcome clinical translation awardee. vivo situation (Xu et al., 1997). Recent evidence suggests that in Correspondence should be addressed to Dr. Alex E. MacKenzie, Children’s addition to supraphysiologic levels of NAIP conferring neuronal Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, Ontario, Canada K1H 8L1. E-mail: [email protected]. protection, the loss of endogenous NAIP results in enhanced Copyright © 2002 Society for Neuroscience 0270-6474/02/222035-09$15.00/0 neuronal vulnerability (Holcik et al., 2000), indicating that NAIP 2036 J. Neurosci., March 15, 2002, 22(6):2035–2043 Maier et al. • Inhibition of Effector Caspases by NAIP BIR Domains plays an important role in regulation of neuronal apoptosis. at room temperature in continuous readings for 30 min [five readings per minute; Cytofluor II; PerkinElmer Life Sciences, Emeryville, CA; ␭ However, a mechanism for antiapoptotic function of NAIP has ␭ excitation (ex), 380 nm; emission (em), 460 nm]. IC50 values were not yet been identified. Although other IAP family members have calculated using the curve-fitting program PROFIT 5.5 for MacIntosh been shown to inhibit caspases directly (Deveraux et al., 1997; (QuantumSoft Inc., Zurich, Switzerland); Ki values were calculated ac- Roy et al., 1997; Tamm et al., 1998), a similar interaction could cording to the formula developed by Cheng and Prusoff (1973). This not be demonstrated for NAIP (Roy et al., 1997), suggesting an formula is valid when the binding is competitive and reversible; we know alternate mechanism in mediating cytoprotection. The present that this is the case for capase-3 and XIAP given the recently published structural analyses of IAP and caspases (Chai et al., 2001; Huang et al., study demonstrates the direct inhibition of effector caspases by 2001; Riedl et al., 2001). Because substrate concentration and Km were ␮ NAIP BIR domains and thus provides a mechanistic explanation kept constant in the assay (both at 10 M), the Ki should approximate half for the cytoprotective effect of NAIP and its function as an of the obtained IC50 value. Ki values were also calculated from the important regulator protein for neuronal apoptosis. steady-state velocities of the enzyme inhibitor complexes using the equa- tions developed by Morrison and Walsh (1988) for the analysis of slow MATERIALS AND METHODS and tight binding inhibitors. This was done in the event that the binding had a marked time dependence and was not wholly competitive and Generation and cloning of NAIP BIR constructs. NAIP constructs encom- reversible, in which case the Cheng and Prusoff (1973) equation would passing one to three BIR domains (see Fig. 2A) were generated by PCR not obtain. The fact that equivalent results were obtained by both using the following primer pairs: B123xt, 5Ј forward primer GGATCC Ј statistical methods supports the accuracy of the inhibitory constants. ATG GCC ACC CAG CAG AAA GCC and 3 reverse primer CTCGAG Culture and survival of primary cortical neurons. Mouse cortical neurons CCA GAT GCC CAC AGA AAA GCT AT; B1, 5Ј forward primer Ј (CD1) were cultured from embryonic day 16 (E16) and grown in defined GGATCC GCA GTT CAG TTG GCA AGG and 3 reverse primer CTC- serum-free medium as described previously (Keramaris et al., 2000). For GAG CTC AGC CTG CTC TTC AGA TT; B2, 5Ј forward primer Ј optimal infection of neurons with minimal cytotoxicity, recombinant GGATCC AGC AGG CTG AGA GAG GT and 3 reverse primer CTC- adenoviral vectors (carrying lacZ, NAIP,orXIAP), at a multiplicity of GAG GTA ATT TCC TCT GAG GAT TTC; B3, 5Ј forward primer Ј infection (MOI) of 10 or 20 pfu/cell, were added to cell suspensions GGATCC TCC TCA GAG GAA ATT ACC and 3 reverse primer CTC- immediately before plating. Neurons were cultured up to day 3 and GAG ATA GGA CCA ACT GCA TTG AA; B12, 5Ј forward primer ␮ Ј subsequently treated either with camptothecin (10 M) alone or with GGATCC GCA GTT CAG TTG GCA AGG and 3 reverse primer CTC- camptothecin and boc-aspartyl(OMe)-fluoromethylketone (BAF; 100 GAG GTA ATT TCC TCT GAG GAT TTC; B23, 5Ј forward primer ␮ Ј M). Cell survival was assessed by using the colorimetric (3-(4,5- GGATCC AGC AGG CTG AGA GAG GT and 3 reverse primer CTC- dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) survival GAG ATA GGA CCA ACT GCA TTG AA; B2A, 5Ј forward primer Ј assay (Cell Titer Kit; Promega, Madison, WI), which measures the GGATCC GCA TCC TTC AGG AAC TGG and 3 reverse primer CTC- conversion by mitochondrial enzymes of the tetrazolium salt to a blue GAG TAT GTC AAC AAA TCC C; B2B, 5Ј forward primer GGATCC Ј formizan salt 24 hr after treatment in an adaptation of the method of ATG AGG TAC CAA GAA GAGG and 3 reverse primer CTCGAG GGG Keramaris et al.
Recommended publications
  • Induced Apoptosis
    APOPTOSIS INDUCTION AND IMMUNOTHERAPY-HOW TO IMPROVE RESULTS OF IMMUNOTHERAPY C/ Professor Peter Hersey University of Newcastle NSW Australia IMMUNOTHERAPY DEPENDS ON INDUCTION OF APOPTOSIS! • IF WE UNDERSTAND THE RESISTANCE MECHANISMS AGAINST APOPTOSIS WE CAN TARGET THESE AND IMPROVE THE RESULTS OF IMMUNOTHERAPY CELL KILLING MECHANISMS USED BY LYMPHOCYTES DEPEND ON INDUCTION OF APOPTOSIS 1. Granzyme – Perforin Mediated Killing CD8 CTL (CD4 CTL) NK Cells and ADCC 2.Death Ligand Mediated Killing TRAIL, FasL, TNF CD4 T Cells Monocytes, Dendritic Cells CURRENTCURRENT CONCEPTSCONCEPTS ININ APOPTOSISAPOPTOSIS TRAIL, Granz B P53.-NOXA, BID CYTOSKELETON PUMA,BAD,BID BIM,BMF Bcl-2,Bcl-xL.Mcl-1 ER Stress, Bik,PUMA,Noxa Bax,Bak Mitochondria Smac,Omi Cyto c, Casp 9 IAPs Classical Pathway Effector Caspases 3,7 MITOCHONDRIAL PATHWAYS TO APOPTOSIS ARE REGULATED BY BCL-2 FAMILY PROTEINS • Pro-apoptotic BH3 only damage sensor proteins (Bid, Bik,Bim, Bmf, Noxa,Puma,Bad,Hrk) • Pro-apoptotic multidomain proteins: BAX, BAK • Anti-apoptotic proteins: BCL-2, BCL-Xl, MCL-1, Bcl-W,A1 WE ALREADY HAVE AGENTS THAT TARGET THE ANTI APOPTOTIC PROTEINS! Targetting Anti Apoptotic Proteins • Genasense against Bcl-2. • Inhibition of production of the IAP protein Survivin YM155 (Astellas Pharm • BH3 mimics that bind Bcl-2 proteins(Abbott ABT-737) Targetting Anti-Apoptotic Proteins • AT-101 (Gossypol) Oral inhibitor of Bcl-2 Bcl- XL,Mcl-1 . Ascenta Therapeutics • TW37- Small mw mimic of Bim that inhibits Bcl-2, Bcl-XL,Mcl-1. Univ Michigan • Obatoclax (GX015-070) Small mw BH3 mimic . Inhibits Bcl-2,Bcl-XL,Mcl-1. (Gemin X) TRAIL INDUCED KILLING REQUIRES DEATH RECEPTORS! TRAIL Induces Apoptosis in the Majority of Melanoma Cell Lines 100 90 80 70 60 50 40 30 % Apoptotic Cells % Apoptotic 20 10 0 1 2 3 4 5 6 7 8 9 101112131415161718192021222324252627282930 Melanoma Cell Lines TRAIL-R1 & R2 Expression Correlates with Degree of Apoptosis L I A 120 120 R T 100 100 y b 80 80 d e 60 60 c u d 40 40 n I s 20 20 si o 0 0 t p -20 o -20 p A -10 10 30 50 70 90 -10 10 30 50 70 90 % TRAIL-R1 TRAIL-R2 Zhang et al.
    [Show full text]
  • Inhibitor of Apoptosis Proteins As Therapeutic Targets in Multiple Myeloma
    Leukemia (2014) 28, 1519–1528 & 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14 www.nature.com/leu ORIGINAL ARTICLE Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma V Ramakrishnan1, U Painuly1,2, T Kimlinger1, J Haug1, SV Rajkumar1 and S Kumar1 The inhibitor of apoptosis (IAP) proteins have a critical role in the control of apoptotic machinery, and has been explored as a therapeutic target. Here, we have examined the functional importance of IAPs in multiple myeloma (MM) by using a Smac (second mitochondria-derived activator of caspases)-mimetic LCL161. We observed that LCL161 was able to potently induce apoptosis in some MM cell lines but not in others. Examining the levels of X-linked inhibitor of apoptosis protein (XIAP), cellular inhibitor of apoptosis protein 1 (cIAP1) and cellular inhibitor of apoptosis protein 2 (cIAP2) post LCL161 treatment indicated clear downregulation of both XIAP activity and cIAP1 levels in both the sensitive and less sensitive (resistant) cell lines. cIAP2, however, was not downregulated in the cell line resistant to the drug. Small interfering RNA-mediated silencing of cIAP2 significantly enhanced the effect of LCL161, indicating the importance of downregulation of all IAPs simultaneously for induction of apoptosis in MM cells. LCL161 induced marked up regulation of the Jak2/Stat3 pathway in the resistant MM cell lines. Combining LCL161 with a Jak2-specific inhibitor resulted in synergistic cell death in MM cell lines and patient cells. In addition, combining LCL161 with death- inducing ligands clearly showed that LCL161 sensitized MM cells to both Fas-ligand and TRAIL.
    [Show full text]
  • 505.Full.Pdf
    Pseudomonas aeruginosa Delays Kupffer Cell Death via Stabilization of the X-Chromosome-Linked Inhibitor of Apoptosis Protein This information is current as of September 26, 2021. Alix Ashare, Martha M. Monick, Amanda B. Nymon, John M. Morrison, Matthew Noble, Linda S. Powers, Timur O. Yarovinsky, Timothy L. Yahr and Gary W. Hunninghake J Immunol 2007; 179:505-513; ; doi: 10.4049/jimmunol.179.1.505 Downloaded from http://www.jimmunol.org/content/179/1/505 References This article cites 44 articles, 21 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/179/1/505.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 26, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Pseudomonas aeruginosa Delays Kupffer Cell Death via Stabilization of the X-Chromosome-Linked Inhibitor of Apoptosis Protein1 Alix Ashare,2* Martha M.
    [Show full text]
  • Blockade of BCL-2 Proteins Efficiently Induces Apoptosis in Progenitor
    Leukemia (2016) 30, 112–123 © 2016 Macmillan Publishers Limited All rights reserved 0887-6924/16 www.nature.com/leu ORIGINAL ARTICLE Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients S Jilg1, V Reidel1, C Müller-Thomas1, J König1, J Schauwecker2, U Höckendorf1, C Huberle1, O Gorka3, B Schmidt4, R Burgkart2, J Ruland3, H-J Kolb1, C Peschel1, RAJ Oostendorp1, KS Götze1 and PJ Jost1 Deregulated apoptosis is an identifying feature of myelodysplastic syndromes (MDS). Whereas apoptosis is increased in the bone marrow (BM) of low-risk MDS patients, progression to high-risk MDS correlates with an acquired resistance to apoptosis and an aberrant expression of BCL-2 proteins. To overcome the acquired apoptotic resistance in high-risk MDS, we investigated the induction of apoptosis by inhibition of pro-survival BCL-2 proteins using the BCL-2/-XL/-W inhibitor ABT-737 or the BCL-2-selective inhibitor ABT-199. We characterized a cohort of 124 primary human BM samples from MDS/secondary acute myeloid leukemia (sAML) patients and 57 healthy, age-matched controls. Inhibition of anti-apoptotic BCL-2 proteins was specifically toxic for BM cells from high-risk MDS and sAML patients, whereas low-risk MDS or healthy controls remained unaffected. Notably, ABT-737 or ABT-199 treatment was capable of targeting the MDS stem/progenitor compartment in high-risk MDS/sAML samples as shown by the reduction in CD34+ cells and the decreased colony-forming capacity. Elevated expression of MCL-1 conveyed resistance against both compounds. Protection by stromal cells only partially inhibited induction of apoptosis.
    [Show full text]
  • Apoptosis Ligand-Induced Enhanced Resistance to Fas/Fas
    Theileria parva-Transformed T Cells Show Enhanced Resistance to Fas/Fas Ligand-Induced Apoptosis This information is current as Peter Küenzi, Pascal Schneider and Dirk A. E. Dobbelaere of October 2, 2021. J Immunol 2003; 171:1224-1231; ; doi: 10.4049/jimmunol.171.3.1224 http://www.jimmunol.org/content/171/3/1224 Downloaded from References This article cites 69 articles, 29 of which you can access for free at: http://www.jimmunol.org/content/171/3/1224.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 2, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Theileria parva-Transformed T Cells Show Enhanced Resistance to Fas/Fas Ligand-Induced Apoptosis1 Peter Ku¨enzi,2* Pascal Schneider,† and Dirk A. E. Dobbelaere3* Lymphocyte homeostasis is regulated by mechanisms that control lymphocyte proliferation and apoptosis. Activation-induced cell death is mediated by the expression of death ligands and receptors, which, when triggered, activate an apoptotic cascade.
    [Show full text]
  • Regulation of Caspase-9 by Natural and Synthetic Inhibitors Kristen L
    University of Massachusetts Amherst ScholarWorks@UMass Amherst Open Access Dissertations 5-2012 Regulation of Caspase-9 by Natural and Synthetic Inhibitors Kristen L. Huber University of Massachusetts Amherst, [email protected] Follow this and additional works at: https://scholarworks.umass.edu/open_access_dissertations Part of the Chemistry Commons Recommended Citation Huber, Kristen L., "Regulation of Caspase-9 by Natural and Synthetic Inhibitors" (2012). Open Access Dissertations. 554. https://doi.org/10.7275/jr9n-gz79 https://scholarworks.umass.edu/open_access_dissertations/554 This Open Access Dissertation is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of ScholarWorks@UMass Amherst. For more information, please contact [email protected]. REGULATION OF CASPASE-9 BY NATURAL AND SYNTHETIC INHIBITORS A Dissertation Presented by KRISTEN L. HUBER Submitted to the Graduate School of the University of Massachusetts Amherst in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY MAY 2012 Chemistry © Copyright by Kristen L. Huber 2012 All Rights Reserved REGULATION OF CASPASE-9 BY NATURAL AND SYNTHETIC INHIBITORS A Dissertation Presented by KRISTEN L. HUBER Approved as to style and content by: _________________________________________ Jeanne A. Hardy, Chair _________________________________________ Lila M. Gierasch, Member _________________________________________ Robert M. Weis,
    [Show full text]
  • The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein
    cells Review The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy Jessica Michie 1,2, Conor J. Kearney 1,2, Edwin D. Hawkins 1,3, John Silke 3,4 and Jane Oliaro 1,2,5,* 1 Peter MacCallum Cancer Centre, Melbourne, VI 3000, Australia; [email protected] (J.M.); [email protected] (C.J.K.); [email protected] (E.D.H.) 2 Sir Peter MacCallum Department of Oncology, The University of Melbourne, VI 3010, Australia 3 The Walter and Eliza Hall Institute of Medical Research, VI 3010, Australia; [email protected] 4 Department of Medical Biology, University of Melbourne, Parkville, VI 3010, Australia 5 Department of Immunology, Monash University, Melbourne, VI 3004, Australia * Correspondence: [email protected]; Tel.: +61-3-8559-7094 Received: 29 November 2019; Accepted: 11 January 2020; Published: 14 January 2020 Abstract: One of the hallmarks of cancer cells is their ability to evade cell death via apoptosis. The inhibitor of apoptosis proteins (IAPs) are a family of proteins that act to promote cell survival. For this reason, upregulation of IAPs is associated with a number of cancer types as a mechanism of resistance to cell death and chemotherapy. As such, IAPs are considered a promising therapeutic target for cancer treatment, based on the role of IAPs in resistance to apoptosis, tumour progression and poor patient prognosis. The mitochondrial protein smac (second mitochondrial activator of caspases), is an endogenous inhibitor of IAPs, and several small molecule mimetics of smac (smac-mimetics) have been developed in order to antagonise IAPs in cancer cells and restore sensitivity to apoptotic stimuli.
    [Show full text]
  • Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions
    cancers Review Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions Haneen T. Salah 1 , Courtney D. DiNardo 2 , Marina Konopleva 2 and Joseph D. Khoury 3,* 1 College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia; [email protected] 2 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; [email protected] (C.D.D.); [email protected] (M.K.) 3 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA * Correspondence: [email protected] Simple Summary: Apoptosis dysergulation is vital to oncogenesis. Efforts to mitigate this cancer hallmark have been ongoing for decades, focused mostly on inhibiting BCL-2, a key anti-apoptosis effector. The approval of venetoclax, a selective BCL-2 inhibitor, for clinical use has been a turning point in the field of oncology. While resulting in impressive improvement in objective outcomes, particularly for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and acute myeloid leukemia, the use of venetoclax has exposed a variety of resistance mechanisms to BCL-2 inhibition. As the field continues to move forward, improved understanding of such mechanisms and the potential biomarkers that could be harnessed to optimize patient selection for therapies that include venetoclax and next-generation BCL-2 inhibitors are gaining increased importance. Abstract: Intrinsic apoptotic pathway dysregulation plays an essential role in all cancers, particularly hematologic malignancies. This role has led to the development of multiple therapeutic agents Citation: Salah, H.T.; DiNardo, C.D.; targeting this pathway.
    [Show full text]
  • The Pseudo-Caspase FLIP(L) Regulates Cell Fate Following P53 Activation
    The pseudo-caspase FLIP(L) regulates cell fate following p53 activation Andrea Leesa,1, Alexander J. McIntyrea,1, Nyree T. Crawforda, Fiammetta Falconea, Christopher McCanna, Caitriona Holohana, Gerard P. Quinna, Jamie Z. Robertsa, Tamas Sesslera, Peter F. Gallaghera, Gemma M. A. Gregga, Katherine McAllistera, Kirsty M. McLaughlina, Wendy L. Allena, Laurence J. Eganb, Aideen E. Ryanb,c, Melissa J. Labonte-Wilsona, Philip D. Dunnea, Mark Wappetta, Vicky M. Coylea, Patrick G. Johnstona, Emma M. Kerra, Daniel B. Longleya,2,3, and Simon S. McDadea,2,3 aPatrick G Johnston Centre for Cancer Research, Queen’s University Belfast, Belfast, Northern Ireland BT9 7BL, United Kingdom; bDiscipline of Pharmacology & Therapeutics, Lambe Institute for Translational Research, School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland; and cRegenerative Medicine Institute, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland Edited by Karen H. Vousden, Francis Crick Institute, London, United Kingdom, and approved June 8, 2020 (received for review February 12, 2020) p53 is the most frequently mutated, well-studied tumor-suppressor switch from cell-cycle arrest to cell death induction remain gene, yet the molecular basis of the switch from p53-induced cell- poorly understood, although p53-mediated transcriptional up- cycle arrest to apoptosis remains poorly understood. Using a combi- regulation of PUMA has been suggested to be crucial in a nation of transcriptomics and functional genomics, we unexpectedly number of studies (10, 11). identified a nodal role for the caspase-8 paralog and only human Despite p53/TP53 being the most frequently mutated gene in pseudo-caspase, FLIP(L), in regulating this switch.
    [Show full text]
  • Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins In
    Published OnlineFirst December 30, 2016; DOI: 10.1158/1078-0432.CCR-16-2172 Review Clinical Cancer Research Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways Adeeb Derakhshan, Zhong Chen, and Carter Van Waes Abstract TheCancerGenomeAtlas(TCGA)hasunveiledgenomic the results of targeting IAPs in preclinical models of HNSCC deregulation of various components of the extrinsic and intrin- using SMAC mimetics. Synergistic activity of SMAC mimetics sic apoptotic pathways in different types of cancers. Such together with death agonists TNFa or TRAIL occurred in vitro, alterations are particularly common in head and neck squa- whereas their antitumor effects were augmented when com- mous cell carcinomas (HNSCC), which frequently display bined with radiation and chemotherapeutic agents that induce amplification and overexpression of the Fas-associated via TNFa in vivo. In addition, clinical trials testing SMAC mimetics death domain (FADD) and inhibitor of apoptosis proteins as single agents or together with chemo- or radiation therapies (IAP) that complex with members of the TNF receptor family. in patients with HNSCC and solid tumors are summarized. Second mitochondria-derived activator of caspases (SMAC) As we achieve a deeper understanding of the genomic altera- mimetics, modeled after the endogenous IAP antagonist tions and molecular mechanisms underlying deregulated SMAC, and IAP inhibitors represent important classes of novel death and survival pathways in different cancers, the role small molecules currently in phase I/II clinical trials. Here we of SMAC mimetics and IAP inhibitors in cancer treatment will review the physiologic roles of IAPs, FADD, and other com- be elucidated.
    [Show full text]
  • Caspase-3 and Inhibitor of Apoptosis Protein(S) Interactionsprovided Byin Elsevier - Publisher Connector Saccharomyces Cerevisiae and Mammalian Cells
    FEBS 24075 FEBS Letters 481 (2000) 13^18 View metadata, citation and similar papers at core.ac.uk brought to you by CORE Caspase-3 and inhibitor of apoptosis protein(s) interactionsprovided byin Elsevier - Publisher Connector Saccharomyces cerevisiae and mammalian cells Michael E. Wrighta, David K. Hanb, David M. Hockenberya;* aMolecular and Cellular Biology Program, Divisions of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA bDepartment of Molecular Biotechnology, University of Washington, Seattle, WA, USA Received 7 August 2000; accepted 11 August 2000 Edited by Vladimir Skulachev optosis proteins (IAPs) [3,4]. The IAPs were originally Abstract Using a heterologous yeast expression assay, we show that inhibitor of apoptosis proteins (IAPs) suppress caspase-3- described by an activity that prevents apoptotic cell deaths mediated cytotoxicity in the order of XIAP s c-IAP2 s c- caused by multiple triggers in Drosophila, Caenorhabditis ele- IAP1 s survivin. The same ordering of IAP activities was gans and mammalian cells [5,6]. Subsequently, several labs demonstrated in mammalian cells expressing an auto-activating demonstrated by in vitro assays that IAPs function as direct caspase-3. The relative anti-apoptotic activities of each IAP inhibitors for speci¢c caspases [7^9]. Speci¢cally, three mam- depended on the particular death stimulus. For IAP-expressing malian IAPs, c-IAP1, c-IAP2, and XIAP, are direct inhibitors cells treated with camptothecin, survival correlated with their of recombinant caspases-3, -7, and -9 [7^9]. This is generally intrinsic anti-caspase-3 activity. However, c-IAP1-transfected accepted to be the principal mechanism for the anti-apoptotic cells were disproportionately resistant to tumor necrosis factor- activity of the IAPs in various experimental settings [4].
    [Show full text]
  • Roles of Bid and XIAP
    Cell Death and Differentiation (2012) 19, 42–50 & 2012 Macmillan Publishers Limited All rights reserved 1350-9047/12 www.nature.com/cdd Review Fas death receptor signalling: roles of Bid and XIAP T Kaufmann*,1, A Strasser2,3 and PJ Jost4 Fas (also called CD95 or APO-1), a member of a subgroup of the tumour necrosis factor receptor superfamily that contain an intracellular death domain, can initiate apoptosis signalling and has a critical role in the regulation of the immune system. Fas-induced apoptosis requires recruitment and activation of the initiator caspase, caspase-8 (in humans also caspase-10), within the death-inducing signalling complex. In so-called type 1 cells, proteolytic activation of effector caspases (-3 and -7) by caspase-8 suffices for efficient apoptosis induction. In so-called type 2 cells, however, killing requires amplification of the caspase cascade. This can be achieved through caspase-8-mediated proteolytic activation of the pro-apoptotic Bcl-2 homology domain (BH)3-only protein BH3-interacting domain death agonist (Bid), which then causes mitochondrial outer membrane permeabilisation. This in turn leads to mitochondrial release of apoptogenic proteins, such as cytochrome c and, pertinent for Fas death receptor (DR)-induced apoptosis, Smac/DIABLO (second mitochondria-derived activator of caspase/direct IAP binding protein with low Pi), an antagonist of X-linked inhibitor of apoptosis (XIAP), which imposes a brake on effector caspases. In this review, written in honour of Juerg Tschopp who contributed so much to research on cell death and immunology, we discuss the functions of Bid and XIAP in the control of Fas DR-induced apoptosis signalling, and we speculate on how this knowledge could be exploited to develop novel regimes for treatment of cancer.
    [Show full text]